What is a stock summary page? Click here for an overview.
Business Description
Protagonist Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US74366E1029
Description
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 38.55 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 26.89 | |||||
| Beneish M-Score | 125.86 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 124.4 | |||||
| 3-Year Book Growth Rate | 20.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -29.07 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.57 | |||||
| 9-Day RSI | 38.71 | |||||
| 14-Day RSI | 46.6 | |||||
| 3-1 Month Momentum % | -2.7 | |||||
| 6-1 Month Momentum % | -13.17 | |||||
| 12-1 Month Momentum % | 37.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.48 | |||||
| Quick Ratio | 12.48 | |||||
| Cash Ratio | 8.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.5 | |||||
| Shareholder Yield % | -0.22 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 58.2 | |||||
| Net Margin % | 63.34 | |||||
| FCF Margin % | 42.08 | |||||
| ROE % | 52.01 | |||||
| ROA % | 46.64 | |||||
| ROIC % | 150.15 | |||||
| 3-Year ROIIC % | 129.22 | |||||
| ROC (Joel Greenblatt) % | 3114.67 | |||||
| ROCE % | 45.88 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 10.77 | |||||
| Forward PE Ratio | 24.58 | |||||
| PE Ratio without NRI | 10.77 | |||||
| Price-to-Owner-Earnings | 19.55 | |||||
| PS Ratio | 6.8 | |||||
| PB Ratio | 4.09 | |||||
| Price-to-Tangible-Book | 4.09 | |||||
| Price-to-Free-Cash-Flow | 14.95 | |||||
| Price-to-Operating-Cash-Flow | 14.85 | |||||
| EV-to-EBIT | 9.69 | |||||
| EV-to-EBITDA | 9.58 | |||||
| EV-to-Revenue | 5.64 | |||||
| EV-to-Forward-Revenue | 15.78 | |||||
| EV-to-FCF | 13.95 | |||||
| Price-to-GF-Value | 0.61 | |||||
| Price-to-Projected-FCF | 16.02 | |||||
| Price-to-Graham-Number | 1.4 | |||||
| Price-to-Net-Current-Asset-Value | 5.28 | |||||
| Price-to-Net-Cash | 7.89 | |||||
| Earnings Yield (Greenblatt) % | 10.32 | |||||
| FCF Yield % | 6.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PTGX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Protagonist Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 434.433 | ||
| EPS (TTM) ($) | 4.2 | ||
| Beta | 1.54 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 0.84 | ||
| Volatility % | 44.73 | ||
| 14-Day RSI | 46.6 | ||
| 14-Day ATR ($) | 2.559974 | ||
| 20-Day SMA ($) | 51.5185 | ||
| 12-1 Month Momentum % | 37.16 | ||
| 52-Week Range ($) | 24.22 - 60.6 | ||
| Shares Outstanding (Mil) | 61.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Protagonist Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Protagonist Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Protagonist Therapeutics Inc Frequently Asked Questions
What is Protagonist Therapeutics Inc(PTGX)'s stock price today?
The current price of PTGX is $45.24. The 52 week high of PTGX is $60.60 and 52 week low is $24.22.
When is next earnings date of Protagonist Therapeutics Inc(PTGX)?
The next earnings date of Protagonist Therapeutics Inc(PTGX) is 2025-05-07 Est..
Does Protagonist Therapeutics Inc(PTGX) pay dividends? If so, how much?
Protagonist Therapeutics Inc(PTGX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers